褚氏安胎方治疗脾肾两虚型先兆流产的临床研究

发布时间：2018-04-21 00:13

本文选题：先兆流产 + 胎漏、胎动不安　；参考：《河南中医药大学》2016年硕士论文

【摘要】：目的:本课题以传统中医理论为指导,在以往实际临床疗效和理论探讨的基础上,进一步对褚氏安胎方治疗脾肾两虚型先兆流产的临床疗效进行分析与评价,并探讨其机理,为先兆流产提供一种安全、有效的中医药治疗方法。方法:本研究共收集在河南中医药大学第二附属医院妇科门诊就诊的60例脾肾两虚型先兆流产患者,采用随机的方法将研究对象分为治疗组(30例)和对照组(30例)。治疗组给予褚氏安胎方加减进行治疗,对照组给予滋肾育胎丸,7天为一疗程,治疗至妊娠满12周。定期检测β-HCG及孕酮水平,B超了解宫内胚胎或胎儿发育情况,观察两组患者治疗前后中医证候改善情况,用药后有无不良反应及对所记录原始资料进行整理,用统计学方法得出结论。结果:治疗前基线比较结果:治疗组与对照组在年龄、妊娠天数、流产次数、症状评分及β-HCG、孕酮等方面的差异均无统计学意义(P0.05),具有可比性;治疗后资料统计结果:治疗组痊愈8例,显效17例,有效4例,无效1例,总有效率为96.7%;对照组痊愈5例,显效11例,有效10例,无效4例,总有效率为86.7%,差异有统计学意义(P0.05),治疗组优于对照组。两组治疗前后血β-HCG水平比较,均有显著统计学差异(P0.01)。两组7周、8周血清孕酮水平相比较,有统计学意义(P0.05),治疗组均优于对照组;两组6-7周血清孕酮水平增长水平比较有差异(P0.05),治疗组优于对照组;两组治疗前后血清孕酮水平比较,均有显著统计学差异(P0.01)。结论:(1)褚氏安胎方治能有效治疗脾肾两虚型先兆流产,提高继续妊娠率,明显改善临床症状,且无明显毒副作用,临床应用安全有效。(2)褚氏安胎方能有效提高患者妊娠8周前血清孕酮水平,提升妊娠早期黄体功能。(3)褚氏安胎方治疗脾肾两虚型先兆流产效果优于滋肾育胎丸,对于临床上脾肾两虚型先兆流产患者更适合,且汤剂能够迅速改善患者先兆流产症状,并增加患者继续治疗的信心。
[Abstract]:Objective: under the guidance of the traditional Chinese medicine theory and on the basis of the practical clinical curative effect and theoretical discussion, the clinical effect of Chu's An-fetus prescription in treating threatened abortion with deficiency of spleen and kidney was further analyzed and evaluated, and its mechanism was discussed. For threatened abortion to provide a safe, effective Chinese medicine treatment. Methods: a total of 60 patients with threatened abortion with deficiency of spleen and kidney were randomly divided into treatment group (n = 30) and control group (n = 30). The treatment group was treated with Chu's Anti Fang, while the control group was treated with Zishen Yuet Pill for 7 days, until the pregnancy reached 12 weeks. The levels of 尾 -HCG and progesterone were detected regularly. B-mode ultrasound was used to understand the development of fetus or embryo, to observe the improvement of TCM syndromes before and after treatment, to observe whether there were any adverse reactions after treatment and to sort out the recorded raw data. Draw a conclusion by statistical method. Results: there were no significant differences in age, pregnancy days, abortion frequency, symptom score, 尾 -HCG and progesterone between the treatment group and the control group (P 0.05). After treatment, 8 cases were cured, 17 cases were effective, 4 cases were effective, 1 case was ineffective, the total effective rate was 96.7in the treatment group, while in the control group, 5 cases were cured, 11 cases were effective, 10 cases were effective, 4 cases were ineffective. The total effective rate was 86.7, the difference was statistically significant (P 0.05), the treatment group was superior to the control group. The serum 尾-HCG levels in the two groups were significantly different before and after treatment (P 0.01). The serum progesterone level of the two groups was significantly higher than that of the control group at 7 weeks and 8 weeks, and the serum progesterone level in the treatment group was better than that in the control group, and the increase level of serum progesterone in the treatment group was better than that in the control group at 6-7 weeks, and the serum progesterone level in the two groups was better than that in the control group before and after treatment. There was significant statistical difference between the two groups (P 0.01). Conclusion Ch'u 's antepartum prescription can effectively treat threatened abortion with deficiency of spleen and kidney, increase the rate of continuous pregnancy, improve clinical symptoms, and have no obvious side effects. The clinical application of Ch'u 's Anti formula can effectively improve the serum progesterone level before 8 weeks gestation and improve the luteal function in the early pregnancy. The effect of Chu's Anti foetus prescription in treating threatened abortion with deficiency of both spleen and kidney is better than that of Zishen Yufen pill. It is more suitable for the patients with threatened abortion with deficiency of spleen and kidney, and the decoction can rapidly improve the symptoms of threatened abortion and increase the confidence of the patients to continue treatment.
【学位授予单位】：河南中医药大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R271.9

【参考文献】